Regulatory News
Tuesday, January 3, 2017
BRIEF-Adamas Pharmaceuticals completes phase 1 clinical trial of ADS-4101 for treatment of partial onset seizures in patients with epilepsy
* Adamas Pharmaceuticals completes phase 1 clinical trial of
ads-4101 for treatment of partial onset seizures in patients
with epilepsy
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment